Navigation Links
Angiotech Expands Quill(TM) SRS product offering receiving FDA 510(k) approval for smaller size diameters of Quill(TM) SRS PDO
Date:5/1/2008

dian securities regulatory authorities or the Securities and Exchange Commission. Given these uncertainties, assumptions and risk factors, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

Quill(TM) is a trademark of Quill Medical, Inc., a wholly-owned

subsidiary of Angiotech Pharmaceuticals, Inc.

(C)2008 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About Angiotech

Angiotech Pharmaceuticals, Inc. is a global specialty pharmaceutical and medical device company with over 1,500 dedicated employees. Angiotech discovers, develops and markets innovative treatment solutions for diseases or complications associated with medical device implants, surgical interventions and acute injury. To find out more about Angiotech (NASDAQ: ANPI, TSX: ANP), please visit our website at http://www.angiotech.com.

CONTACT: Deirdre Neary, Manager, Investor Relations and Corporate Communications, Angiotech Pharmaceuticals, Inc., (604) 222-7056, dneary@angio.com


'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Angiotech elects to suspend Vascular Wrap(TM) pivotal clinical trials
2. Angiotechs Corporate Partner, Boston Scientific, Reports Canadian Approval for TAXUS(R) Liberte(R) Stent System
3. Angiotechs novel 5-FU Central Venous Catheter receives FDA 510(k) clearance
4. Angiotech announces director resignation
5. Angiotech announces commercial launch of Cook Medicals Zilver(R) PTX(TM) drug-eluting peripheral stent in New Zealand
6. Angiotech to participate in Credit Suisse Global Leveraged Finance Conference
7. 960-Patient Study Demonstrates Zero Blood Stream Infection In Patients Treated With Angiotechs Novel 5-FU Central Venous Catheter
8. Angiotech to participate in Lehman Brothers Healthcare Conference
9. Angiotech announces filing of audited financial results for the year ended December 31, 2007 and restatement of results for the year ended December 31, 2006
10. Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter
11. Angiotech showcases its Hemostream(TM) Dialysis Catheter at the Society of Interventional Radiology (SIR) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/11/2014)... a one atom thick sheet of carbon, can be ... form of graphene that could have a significant impact ... paint, it could provide an ultra-strong, non-corrosive coating for ... oxide solutions can be used to paint various surfaces ... After a simple chemical treatment, the resulting coatings behave ...
(Date:9/11/2014)... 11, 2014 XBiotech announced today it has ... that the Company says will be used to dramatically ... is designed to fill, stopper and crimp vials, which ... the unit is said to contain an in-line feed ... a high level of quality compared to less sophisticated ...
(Date:9/11/2014)... 2014 The Registration Committee today ... now open for Pittcon 2015, the world’s largest ... event will be held March 8-12, 2015, at ... , The discounted registration fee of $175 ... 2/20/2015). This affordable price includes unlimited week-long access ...
(Date:9/11/2014)... (PRWEB) September 11, 2014 CollabRx, ... and IT systems that support clinical decision-making in ... Service that now supports the interpretation of copy ... a single, user-friendly report that contains clinically relevant ... toward cancer treatment planning and support of clinical ...
Breaking Biology Technology:Graphene paints a corrosion-free future 2Conferee Registration Opens for Pittcon 2015; Housing & Travel Open for Reservations 2CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data 2CollabRx Launches Expansion of Its Genetic Variation Annotation Service to Support Copy Number Variation (CNV) Data 3
... Aug. 3, 2011 Omeros Corporation (NASDAQ: ... and commercializing products focused on inflammation, bleeding and disorders ... A. Demopulos, M.D., chairman and chief executive officer, is ... 2011 Canaccord Genuity Growth Conference August ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... - discovering the pharma and diagnostics ... What are the ...
... Inc. (Nasdaq: ANDS ) announced today that it ... 8, 2011, after the U.S. financial markets close. ... August 8, 2011, at 5:00 p.m. Eastern Daylight Time to ... live webcast of the call will be available online at ...
Cached Biology Technology:Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 2Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 3Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 4Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 5Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 6Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 7Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 8Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 9Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 10Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 11Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 12Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 13Biomarkers: Technological and Commercial Outlook 2011-2021 - Discovering the Pharma and Diagnostics Opportunities 14Anadys Pharmaceuticals to Report Second Quarter 2011 Financial Results 2
(Date:9/11/2014)... University researchers and their international colleagues have created ... of neutral evolution in the biogeographic distribution of ... in the journal Science . The papertitled ... neutral agent-based model"was co-authored by Ferdi Hellweger, a ... civil and environmental engineering; his doctoral student Neil ...
(Date:9/11/2014)... (Sept. 11, 2014)Scientists today unveiled what appears to be ... aegyptiacus . New fossils of the massive Cretaceous-era predator ... 95 million years ago, providing the most compelling evidence ... hunt in an aquatic environment. The fossils also indicate ... dinosaur to roam the Earth, measuring more than 9 ...
(Date:9/11/2014)... Rice Research Institute of Iran have discovered that ... and Asia, has changed its host preferences in order to ... this adaptation for biological control of problematic weeds in rice ... plant have been described in the open access journal ... G. permixtana have been so far reported to ...
Breaking Biology News(10 mins):Microbes evolve faster than ocean can disperse them 2Scientists report first semiaquatic dinosaur, Spinosaurus 2Scientists report first semiaquatic dinosaur, Spinosaurus 3Scientists report first semiaquatic dinosaur, Spinosaurus 4Unusual host preference of a moth species could be useful for biological control 2
... For millions of Americans with Type-2 diabetes and inject ... associated risk of cancer is of increasing concern. Studies ... produced by the body or injected in synthetic form ... With the release of today,s study, "Supramolecular ...
... University of Illinois scientists have learned that a specific ... health. "In experiments with mice, we knocked out ... body to make arachidonic acid. Without arachidonic acid, the ... itchy, they scratched themselves continuously, and they developed a ...
... More than one third of Americans are considered obese ... mass index (BMI) greater than 40. The April issue of ... on the ever-increasing use of bariatric surgery to control the ... important role that registered dietitians play in the management of ...
Cached Biology News:Case Western Reserve team discovers 'smart' insulin molecule 2U of I study: Lack of omega-6 fatty acid linked to severe dermatitis 2Registered dietitians play essential role in management of gastric bypass patients 2Registered dietitians play essential role in management of gastric bypass patients 3
... expression of an N-terminal FLAG® fusion and ... marker from bicistronic mRNA. Two genes ... for transcription of a single message from ... for protein-protein interaction studies, multi-subunit proteins, and ...
Mouse monoclonal antibody raised against a partial recombinant PRG4. NCBI Entrez Gene ID = PRG4...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Mouse monoclonal antibody raised against a partial recombinant ZNF167. NCBI Entrez Gene ID = ZNF167...
Biology Products: